RxDoctor Payments Data

Maryam Fathi

Adult Health · West Hills, CANPI 1457088247

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,730, more than ten times the $56 reported in 2022. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,710in general payments, 2019–2025

Across 228 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$818
  • Johnson & Johnson$666
  • Phathom Pharmaceuticals, Inc.$626
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$602
  • Madrigal Pharmaceuticals$540
  • Pfizer$482
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,62699%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,710 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$53,036
Medicare patients
359
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide18$17,884
Omeprazole116$1,586
Famotidine79$952
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$871
Pantoprazole Sodium29$719
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$304
Hydrocortisone14$221
Metronidazole12$83
Losartan Potassium12$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$818$17,88418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.

Other adult health in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →